MediMix Oncology
  • Home
  • Congresses
    • 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • WCLC 2025
      • ESMO GI 2025
      • ASCO 2025
      • EADO 2025
      • ELCC 2025
      • ENETS 2025
  • What’s new doc
    • Breast Cancer
    • GI Cancer
    • GU Cancer
    • Lung Cancer
  • Webinars
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
ELCC 2024Lung Cancer

A propensity-based analysis of SBRT & VATS for early-stage lung cancer

4 April 2024

Dr Olivier Van Kerkhove, pulmonologist in training at UZ Leuven presented a propensity-based analysis of SBRT and VATS for early-stage lung cancer that can guide data-driven support and decision-making in a multidisciplinary tumour board, especially for patients in the ‘grey zone’.

With the educational support of:

You may also be interested in:

FLAURA2 post-progression outcomes

A network meta-analysis of perioperative IO for resectable NSCLC

Updated safety data of AEGEAN study

Tags:

poster

Share Article

Website created by MediMix © 2025 - Privacy Policy

  • Home
  • Congresses
    • 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • WCLC 2025
      • ESMO GI 2025
      • ASCO 2025
      • EADO 2025
      • ELCC 2025
      • ENETS 2025
  • What’s new doc
    • Breast Cancer
    • GI Cancer
    • GU Cancer
    • Lung Cancer
  • Webinars
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.